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Abstract
Virological failure on a boosted-protease inhibitor (PI/r) first-line triple combination is usually not associated with the
detection of resistance mutations in the protease gene. Thus, other resistance pathways are being investigated. First-line PI/
r monotherapy is the best model to investigate in vivo if the presence of mutations in the cleavage sites (CS) of gag gene
prior to any antiretroviral treatment might influence PI/r efficacy. 83 patients were assigned to initiate antiretroviral
treatment with first-line lopinavir/r monotherapy in the randomised Monark trial. We compared baseline sequence of gag
CS between patients harbouring B or non-B HIV-1 subtype, and between those who achieved viral suppression and those
who experienced virological failure while on LPV/r monotherapy up to Week 96. Baseline sequence of gag CS was available
for 82/83 isolates; 81/82 carried at least one substitution in gag CS compared to HXB2 sequence. At baseline, non-B subtype
isolates were significantly more likely to harbour mutations in gag CS than B subtype isolates (p,0.0001). Twenty-three
patients experienced virological failure while on lopinavir/r monotherapy. The presence of more than two substitutions in
p2/NC site at baseline significantly predicted virological failure (p=0.0479), non-B subtype isolates being more likely to
harbour more than two substitutions in this specific site. In conclusion, gag cleavage site was highly polymorphic in
antiretroviral-naive patients harbouring a non-B HIV-1 strain. We show that pre-therapy mutations in gag cleavage site
sequence were significantly associated with the virological outcome of a first-line LPV/r single drug regimen in the Monark
trial.
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Introduction
Complete viral suppression may be achieved in 64 to 84% of
antiretroviral-naı ¨ve HIV-infected patients starting a ritonavir-
boosted protease inhibitor based first-line combination [1–4].
Unlike virological failure on a first-line non-nucleoside analogue
reverse transcriptase inhibitor (NNRTI)-containing regimen,
failure on a first-line PI/r based triple combination is rarely
associated with the detection of resistance mutations in HIV
protease and reverse transcriptase genes [1,4,5]. Indeed, the
development of PI resistance is usually a stepwise process
occurring in treatment-experienced patients, with first the
accumulation of major mutations leading to resistance to one or
several protease inhibitors and decreasing viral fitness [6–8], and
then, minor mutations, which partially subsequently restore viral
replication [9–12]. The fact that failure on a first-line PI/r
combination is rarely associated with the detection of resistance
mutations has led to the search for other resistance mechanisms
enabling HIV to become resistant to PI without modification of
the viral protease. One hypothesis might be that mutations are
selected outside the protease gene, i.e. in the gag gene.
The HIV protease cleaves the gag and gag-pol polyproteins by
interacting with specific cleavage sites (CS) in gag and pol genes. In the
product of the gag open reading frame, Gag polyproteins are cleaved
at five cleavage sites into p17 (MA), p24 (CA), p2 (SP1), p7 (NC), and
p6gag. In the product of the gag-pol open reading frame, Gag-Pol
polyproteins are cleaved at eight cleavage sites into p17 (MA), p24
(CA), p2 (SP1), p7 (NC), transframe protein (TFP), p6pol, protease,
reverse transcriptase, and integrase [13,14]. Frameshifting is required
for producing Gag and Gag-Pol polyprotein precursors in HIV-1,
similar to many other retroviruses. Frameshifting is a rare controlled
e v e n t ,o c c u r r i n go n l yf o r1o f1 0t o2 0r i b o s o m e s .I ti sd r i v e nb yt h e
secondary RNA structure also called hairpin structure and allows for
a correct Gag/Gag-Pol ratio to ensure optimal virus activity [15,16].
TheRNAfoldingand stabilityofthegag-polframeshiftregion can be
evaluated by the measure of hairpin free energy.
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enabling specific protease mutants to have a greater efficiency of
cutting the Gag polyprotein [9,12,17,18]. Interestingly, after full
genomic sequencing, Nijhuis et al. reported on three viruses
resistant to a novel PI without any resistance-associated mutation
in protease gene but harbouring NC/p1 CS substitutions in the viral
Gag polyprotein (K436E and or I437T/V) in [19]. This effect was
driven essentially by the C-terminal region. Mutations in NC-SP2-
p6 gag CS were found indeed to confer a 3- to 6-fold increase in
phenotypic resistance factors to PIs and/or to enhance PI
resistance conferred by mutations in the protease gene [20,21].
Potential underlying mechanisms of resistance may involve an
increase in the mutant protease activity by a compensatory
mechanism and/or a higher level of production of protease.
Though substitutions in gag CS are detected often in PI-
experienced HIV-infected patients [22], recent studies have shown
that such substitutions are also evident in antiretroviral-naı ¨ve
HIV-infected patients [19,23]. Moreover, Nijhuis et al showed
that these CS substitutions were highly significantly associated with
reduced susceptibility to PI in clinical isolates lacking primary
protease mutations [19]. Thus, in antiretroviral-naı ¨ve HIV-
infected patients starting a first-line combined antiretroviral
therapy (cART), the presence of CS mutations might be associated
with a decreased activity of protease-containing regimens, but its
impact on cART outcome might be less pronounced in a context
of triple combination with two nucleoside reverse transcriptase
inhibitors (NRTI).
Monark was the first randomized trial comparing the efficacy of
lopinavir/r (LPV/r) single drug regimen with a classical triple
combination in antiretroviral-naı ¨ve HIV-infected patients starting
a first-line regimen [24,25]. In this study, the proportion of
patients achieving complete viral suppression was lower in the
LPV/r single drug arm than in the triple combination arm.
However, only 5 patients out of the 23 experiencing virological
failure while on LPV/r drug selective pressure harbored a viral
strain with major PI resistance-associated mutations [26]. First-line
LPV/r monotherapy represents the ideal model to investigate
whether the presence of pre-therapeutic mutations in gag CS is
associated with virological failure in the absence of protease-
associated resistance mutations. We therefore sequenced gag CS at
baseline in all 83 viral isolates from patients randomised to LPV/r
single drug regimen in the Monark trial and then compared
baseline sequence of gag CS between patients achieving full
virological suppression and those experiencing virological failure
while on LPV/r single drug selective pressure. We also sequenced
gag CS at the time of virological failure to look for additional
mutations that would have been selected under drug-selective
pressure.
Methods
Monark study design
Monark study design has been described elsewhere [24]. The
study protocol was approved by the Ethics Committees in each
participating country (France: Comite ´ d’Ethique de l’Ho ˆpital de
Bice ˆtre; Germany: Ethik-Kommission der Aerztekammer Berlin,
Ethikkommission Charite ´ Universita ¨tsmedizin Berlin, Ethikkom-
mission Heinrich Heine-Universitaet Dusseldorf, Ethikkommission
Bayerische Landesaerztekammer Muenchen; Spain: Comite ´E ´tico
de Investigacio ´n Clı ´nica Barcelona; Italy: Comitato Etico Brescia,
Comitato Etico Torino, Comitato Etico della Fondazione Milano,
Comitato Etico Locale per la Sperimentazione Clinica dell’Ospe-
dale Luigi Sacco di Milano, Comitato EticoR Roma; and Poland:
Komisja Bioetyczna Warsaw). All patients provided written
informed consent. Briefly, patients were randomly assigned to
receive first-line LPV/r monotherapy or LPV/r plus ZDV/3TC if
they were naı ¨ve to antiretroviral therapy, had a CD4 cell count
above 100/mm
3, a plasma HIV-1 RNA below 100 000 copies/
mL and no evidence of drug-resistance at screening visit. The
primary endpoint was the proportion of patients with plasma
HIV-1 RNA below 400 copies/mL at week 24 (W24) and below
50 copies/mL at W48. Follow up until W96 was planned for
evaluation of the long-term safety and efficacy of the LPV/r
monotherapy arm [25]. Sub-optimal response was defined as (i)
failure to achieve a decline in viral load of at least 1.0 log10 copies/
mL by W4, (ii) failure to achieve a viral load below 400 copies/mL
by W24 and (iii) any viral rebound $1 log, after an HIV-1
RNA,400 copies/mL, confirmed by a second measurement at
least 14 days later.
Resistance testing
Reverse transcriptase and protease genotypic resistance tests
were performed at screening and at the time of VF according to
the trial definition [26]. The resistance analysis was extended also
to patients with low-level viremia (between 50 and 400 copies/mL)
after W24. Thirty-three patients experienced VF during the study
course: 23/33 were on LPV/r single drug regimen at the time of
VF and the remaining ten had discontinued study treatment. Gag
resistance testing was focused on patients experiencing VF while
under LPV/r drug selective pressure (n=23). Protease inhibitor
(PI) resistance mutations were defined according to 2008 IAS list
(www.iasusa.org).
Determination of viral subtype
The HIV-1 subtype was determined after phylogenetic analysis
of the reverse transcriptase sequences as previously described [26].
We analyzed gag CS mutations according to subtype B and other
subtypes as non B.
Amplification and Analysis of Gag region
Gag genes were sequenced at baseline in all patients randomized
to LPV/r monotherapy and at the time of confirmed virological
failure. Viral RNA was extracted from plasma stored at 270uC
using QIAampH RNA Mini Kit (Qiagen SA, Courtaboeuf,
France). Amplification and sequencing were done with primers
as previously described [19]. All sequences were centralized at the
Necker Virology Laboratory.
Different CS gag appellations have been used over time (the
ones used in recent literature are between bracket). Differences in
frequency of amino acid sequences for CS CA/p2 (or p24/p2),
p2/NC (or p2/p7), NC/p1 (or p7/p1), p1/p6gag in the gag reading
frame, transframe protein (TFP), TFP/p6
pol and p6
pol/PR in the
gag-pol reading frame, with respect to the wild-type virus HXB2
were studied. Mixtures containing wild-type and mutant variants
were scored as mutant.
Determination of hairpin free energy
Baseline RNA folding and the stability of the hairpin structure
of the gag-pol frameshift region were determined using measure-
ment of free energy in accordance with Turner’s rules (CombFold,
RNAsoft [http://www.rnasoft.ca/cgi-bin/RNAsoft/CombFold/
combfold.pl]).
Statistical analysis
The distribution of gag CS mutations was described according
to HIV-1 subtype B and non-B at baseline in all samples and at the
time of virological failure in 23 patients. Fisher’s exact test for
Mutations in Gag and Response to PI/r Monotherapy
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were used to compare groups of patients. A multivariate logistic
regression was used to identify independent significant factors
associated with virological outcome. The variables investigated
included the presence or absence of substitutions at position A374
or V484 or S451 in gag CS at baseline, B versus non-B subtype
and sub-optimal (having missed at least one dose of study
treatment between baseline and Week 96) versus good adherence
(no missed dose throughout follow-up).
Results
Baseline gag CS mutations and impact on virological
response
Gag gene sequence was available for 82 among the 83 patients
randomized to LPV/r monotherapy and followed until W96. At
baseline, 81/82 isolates carried at least one substitution in gag CS
compared to HXB2 sequence, with a median number of 3 (range
0–10): 4/82 isolates carried at least one substitution in CA/p2, 76/
82 in p2/NC, 15/82 in NC/p1, 45/82 in p1/p6 site in the gag
reading frame, and 80/82 in TFP/p6
pol and 81/82 in p6
pol/PR in
the gag-pol reading frame. Among the gag CS mutations in the gag
reading frame previously described in therapy-experienced isolates
(A431V, K436R, I437V, L449F/V, P452S, P453L/A) [23], the
K436R mutation was evident at baseline in 6 patients, the I437V
mutation in 2, the L449F mutation in 1 and the P453L mutation
in 5 patients.
HIV-1 subtype distribution was well balanced at baseline
between the two treatment groups. For patients on LPV/r
monotherapy, the distribution of viral subtype was as follows: 56
B subtype (68%) and 27 non-B subtypes including CRF02_AG
16%, A 2%, G 4% and others subtypes 10%. Figure 1 describes
the distribution of gag CS mutations according to HIV subtype.
Non-B subtype isolates were significantly more likely to harbour
more than two substitutions in p2/NC site (88% vs 32%,
p,0.0001), more than three substitutions in the TFPp6pol site
(100% vs 54%, p,0.0001) and more than three substitutions in
the p6pol site (50% vs 14%, p,0.0001) than B subtype isolates,
respectively (Figure 1).
Of note, the level of hairpin free energy was significantly higher
in B viruses (median 223.35 kcal/mol, Inter Quartile Range
223.95 to 221.75) compared with non-B viruses (median
220.85 kcal/mol, IQR 222.10 to 220.0) (p=0.0005).
The impact of baseline substitution in gag CS on subsequent
LPV/r single-drug regimen treatment outcome was analyzed.
Amino-acid residues G, T, N, P and S at position A374 in the gag
reading frame tended to predict virological failure (p=0.053).
Substitutions at position A374 were significantly more likely in
non-B subtype (70%) versus B subtype viruses (36%, p=0.005).
Amino-acid residues G, I, P and S at position V484 in the gag-pol
reading frame were significantly associated with virological failure
(p=0.024). Non-B subtype viruses were significantly more likely to
harbour substitutions at position V484 (85%) than B subtype
viruses (13%, p,0.001). In contrast, amino-acid residues G, N and
R at position S451 in gag reading frame were significantly
associated with virological success (p=0.026). The presence of
more than two substitutions in p2/NC site at baseline significantly
predicted virological failure (p=0.0479). In contrast, the presence
of at least three substitutions in the TFPp6pol site or in the p6pol
site was not associated with virological failure. Only the presence
of substitutions at positions V484 (OR=4.87 (IQR 1.6–14.8),
p=0.005) and S451 (OR=0.12 (IQR 0.02–0.6), p=0.01) re-
mained significantly associated with subsequent virological out-
come in multivariate analysis.
No impact of folding and stability of gag-pol RNA frameshift on
virological response was observed.
Evolution of gag cleavage site mutations in patients
experiencing virological failure
Twenty-three patients experienced virological failure while on
LPV/r during the study course. Table S1 focuses on positions at
which codons changes where evident at baseline and at the time of
virological failure. Compared to baseline sequences, additional
substitutions in gag CS were evident in 11/23 patients (in CA/p2
(n=2), in p2/NC (n=3), in p1/p6 (n=2), in TFP/p6pol (n=3),
in p6pol (n=1)). Reversions to wild type amino-acid residue were
observed in 9/23 patients (in CA/p2 (n=1), in p2/NC (n=4), in
TFP/p6pol (n=3), in p6pol (n=1)).
When focusing on gag CS mutations usually detected in
treatment-experienced isolates (A431V, K436R, I437V, L449F/
V, P452S, P453L/A), the L449F mutation was not detected at
baseline and emerged at the time of failure in 2 cases (patients
#507, #1401). For these two patients, no minor or major changes
in protease gene were evidenced.
PI major resistance mutations were evidenced at the time of
virological failure in 5 patients as described previously [26].
Emergence of major PI resistance mutations was associated with
concomitant change in gag CS in 3/5 isolates (Table S1, patients
#311, #3002, #3103). Baseline number and gag CS mutation
was not associated with the selection of additional major PI
mutation at virological failure.
Discussion
The major result of the MONARK trial was that LPV/r
monotherapy demonstrated lower rates of virological suppression
when compared to LPV/r triple therapy [24]. In addition, long-
term 96-week follow-up data are available for patients randomised
to first-line LPV/r single drug regimen [25]. Intriguingly, in most
patients experiencing virological failure, this was not explained by
the emergence of resistance mutations in the protease gene while
under protease inhibitor drug-selective pressure [26]. Moreover
analysis of predictive factors of virological response in patients
randomized to LPV/r single drug regimen indicated that having a
plasma HIV-RNA load below 400 copies/ml at week 4 and
harbouring an HIV-1 subtype B were independently associated
with an increased probability of success [27]. Here we first show
that gag CS and the gag-pol frameshift region were highly
polymorphic especially in patients infected with a non-B subtype
strains. Second, the presence of mutations in gag CS prior to any
antiretroviral therapy influences virological outcome of a first-line
PI/r single-drug regimen. However, given that (i) the gag
substitutions previously showing an association with reduced PI
susceptibility in the absence of protease resistance mutations, or
reduced susceptibility/increased replicative capacity in their
presence are not those showing an association with virological
failure in this study, (ii) the study of the gag region in patients
undergoing virological failure does not show any significant
accumulation of substitutions from baseline and (iii) the baseline
substitutions associated with virological failure do not accumulate
at failure and are not associated with the emergence of minor or
major protease resistance mutations at failure, it might be argued
that the highest rate of virological failure was more likely related to
suboptimal adherence among patients harbouring a non-B
subtype compared to those harbouring a B subtype [27].
Multivariate analysis showed that the detected association between
the gag polymorphisms and virological outcome remained
independent from patients adherence.
Mutations in Gag and Response to PI/r Monotherapy
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polymorphic at baseline in the 82 assessable patients, especially
those infected with a non-B subtype strains. The most polymor-
phic gag CS were the p2/NC site in the gag reading frame and
both TFP/p6pol and p6pol sites in the gag-pol reading frame.
Interestingly, the presence of more than two substitutions in p2/
NC site at baseline was significantly associated with virological
failure, non-B subtype isolates being more likely to harbour more
than two substitutions in this specific site. This result brings now
some light on our previous finding which suggest that, in spite of
potential confounding factor evidenced in this study (adherence
and non-B subtype), virological failure appeared significantly more
frequent in non-B (46%) than in B subtype isolates (20%,
p=0.0479) [27].
Several studies reported that the p2/NC CS is highly
polymorphic [22,28,29] with a statistically significant association
between these mutations and the development of high-level PI
cross-resistance [28]. Indeed, selection of mutation at position 373
in p2/NC correlated with poor virological response in a context of
mutated protease [22]. In our study, the presence of mutations at
position 374 at baseline tended to predict virological failure. This
was true in a context of wild-type protease, suggesting that this
mutation might be a first step towards the development of high
level resistance if protease-associated mutations were to emerge
subsequently.
Recently, the impact of the natural polymorphism in gag gene of
non-B subtype isolates was evaluated in vitro on the drug
susceptibility and the catalytic efficiency of the protease ([30,31].
Introduction of a CRF01_AE-gag/PR region in a background of
subtype B pNL4-3 virus (CRF01_AE-gag/PR recombinant) clearly
showed that these viruses were significantly less susceptible to 9 PIs
than the CRF01_AE-PR-recombinant viruses (without AE gag
region) [31], which is consistent with a relevant impact of the
polymorphism of CRF01_AE gag on PI susceptibility. In keeping
with Jinnopat et al, Gupta et al demonstrated that full-length HIV-1
Gag from A or C subtype HIV-1 strains can contribute to 3 to 14
fold change of reduction in lopinavir susceptibility [30]. Authors
concluded that considering the protease gene alone in a genetic
background of B subtype may overestimate PI susceptibility.
Finally, in keeping with previous reports [32–34], we found that
the level of hairpin free energy was higher in B than in non-B
subtypes. It has been shown that a decrease in free energy of the
RNA secondary structure of the gag-pol frameshift signal induces
instability in this signal, poor efficiency of change in the gag-pol
open reading frame and a diminution of enzyme production.
Protease gene of non-B subtypes displays a high degree of
polymorphism that potentially alters the susceptibility of the
protease to PIs [35,36]. Indeed, phenotypic studies revealed that
naturally occurring amino acid substitutions found in protease gene
of non-B subtypes can affect the drug susceptibility of the protease
[37–39].
Mutations K436R, I437V, L449F and P453L in gag CS,
previously evident in treatment-experienced isolates [23], were
present at baseline in 13/82 (16%) patients but were not associated
with virological failure. Our results are in keeping with Verheyen
et al, who showed that the prevalence of K436R, I437V and
P453L was higher in antiretroviral-naı ¨ve patients infected with
non B subtypes than with a B subtype [40]. These polymorphisms
observed at positions 436, 437, 449, and 453 might influence the
selection of treatment-associated CS substitutions at these
positions.
Recently, in the 2IP-ANRS 127 trial evaluating a first-line dual-
boosted PI regimen in naı ¨ve patients, Larrouy et al demonstrated
that the presence of gag CS mutation 128 (p17/p24) and mutation
449 (p1/p6gag) at baseline were associated with subsequent
virological failure [33]. We did not find such an association in the
Monark trial. Results from 2IP might however hardly be
extrapolated to the Monark trial because the PIs used were
different (fosamprenavir-atazanavir/r and saquinavir-atazanavir/r
versus lopinavir/r) as well as the definition and the time of
assessment of virological failure (week 16 in the 2IP trial versus
week 96 in the Monark trial). Follow-up was longer in the Monark
trial (96 weeks), thus we can not compare directly the impact of the
gag region on the selection of PI major mutation between the two
studies.
Most virological failures were not associated with specific
changes in Gag sequence at the time of failure. Of note, the
selection of the mutation L449F was evident at the time of failure
in two patients. As previously described, this mutation was
observed only in protease inhibitor-experienced patients with
protease resistance mutations [22,23]. L449F was evident in
association with the I50V in the protease gene, increasing the level
Figure 1. Frequency of gag cleavage site mutations at baseline according to HIV-1 B and non-B subtype. The gag cleavage sites
mutations are described on the gag and the gag-pol reading frames. Frequencies of mutations are presented according to HIV-1 subtype (B in grey
and non-B in black).
doi:10.1371/journal.pone.0024798.g001
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mutation might act as compensatory mutation allowing an
increase of the cleavage activity of the mutant protease. In our
case, we can speculate that the emergence of the L449F mutation
could precede and/or promote the selection of the I50V mutation
under LPV/r monotherapy selective pressure. Further phenotypic
analysis of clonal isolates harbouring the L449F might help
understanding the decreased susceptibility to lopinavir.
Major PI mutations were evident in 5 patients among the 23
experiencing virological failure and studied in the present analysis.
There was no consistent association between the emergence of
major PI resistance mutations and baseline Gag CS region or
changes in Gag sequence at the time of virological failure. We
previously reported the selection of the L76V major PI mutation in
3 patients, all three infected with HIV-1 CRF02_AG subtype,
confirming that the L76V mutation (+/2 the M46I mutation) is a
novel resistance pathway emerging during failure on a first line
LPV/r-based regimen [41–43]. Nijhuis and others suggested that
the L76V mutation was associated with the emergence of the
A431V mutation in the NC/p1 (p7/p1) site, thus compensating
the severe reduction in replicative capacity of the L76V mutant
[43]. In contrast to previous reports, the A431V mutation was not
selected in our study, even in patients with the L76V mutation at
virological failure, which might be due to the CRF02_AG
particular genetic background. Of note, mutation A431V might
have been selected later in our patients if drug selective pressure
was maintained with an ongoing viral replication.
In conclusion, we show that pre-therapy mutations in gag
cleavage site sequence were significantly associated with the
virological outcome of a first-line LPV/r single drug regimen, in
spite of the absence of consistent association with either the
emergence of major PI resistance mutations or with changes in gag
sequences at the time of virological failure. Gag cleavage site is
highly polymorphic in antiretroviral-naive patients harbouring a
non-B HIV strain. The non-B subtype may be associated with a
high risk of virological failure on first-line LPV/r monotherapy.
Our results, together with the similar outcome between B and
non-B HIV-1 strains with PI/r-based triple combinations [44,45]
suggest that the impact of mutations in gag CS might be less
critical in a context of PI/r-based triple combination (with drugs
acting on another target than protease gene) than in a PI/r
monotherapy setting. Further studies are warranted to better
understand the determinants and prognostic factors of virological
outcome of non-B HIV-1 strains in a setting of PI/r monotherapy,
especially if the LPV/r monotherapy strategy is proposed as a
second-line option after failure on a NNRTI-based first-line triple
combination in resource-limited countries [46,47] where non-B
HIV-1 subtypes are predominant.
Supporting Information
Table S1 GAG cleavage site and protease mutations at
screening and at failure in the 23 patients who experienced
virological failure.
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